SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day, taking place on the 18th-20th November 2019 in London, UK. The global ophthalmic drug market size is ...

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

EDTA has gained use in ophthalmic solutions owing to its ability to bind metals. Therapeutically, EDTA has been used to remove calcified plaques that occur in the superficial cornea in band ...

The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore ...

Eye drops are the most preferred drug delivery method in the ophthalmic market, yet developing eye drop formulations targeting the retina, located in the posterior segment of the eye, remains a ...

VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...

Glaukos submitted a new drug application to the FDA for Epioxa ... closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA approved, noninvasive ...

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

An assortment of different preservative formulations has been used in ophthalmic medicines and many of these preservatives have been linked to unwanted ocular surface side effects. Benzalkonium ...